15. Related Party Transactions |
12 Months Ended | |||
|---|---|---|---|---|
Dec. 31, 2020 | ||||
| Related Party Transactions [Abstract] | ||||
| Related Party Transactions |
The Company has entered into various research, development, license and supply agreements with Serum Institute and Pharmsynthez (including SynBio), each a related party whose relationship, ownership, and nature of transactions is disclosed within other sections of these footnotes. Please refer to Note 4, Significant Strategic Collaborations, and Note 7, Goodwill, Indefinite-Lived Intangible Assets and Other Long-Term Assets, for details on arrangements with collaboration partners that are also related parties.
On July 19, 2019, the Company acquired the XCART technology platform from Hesperix and OPKO. Dr. Genkin is a director of the Company and was a significant shareholder of Hesperix. In addition, the Company repaid an approximate $225,000 loan that Dr. Genkin entered into with Hesperix. Mr. Adam Logal, one of our directors, is Senior Vice President, Chief Financial Officer, Chief Accounting Officer and Treasurer of OPKO Health, Inc., the parent company of OPKO. |